← Back to Search

Procedure

Neurointerventional for Pseudotumor cerebri

N/A
Waitlist Available
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1,3,6,12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new treatment called venous sinus stenting for patients with Increased Intracranial Hypertension (IIH) who don't get better with standard treatments. The stent is a small tube placed in a brain vein to keep it open, which helps lower pressure inside the head. This can improve symptoms like headaches and vision problems. Venous sinus stenting has shown promising results in treating patients with idiopathic intracranial hypertension (IIH) who are refractory to medical treatment.

Eligible Conditions
  • Pseudotumor cerebri

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1,3,6,12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1,3,6,12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Normalized CSF pressure post venous stenting
Secondary study objectives
Assess the long-term success of this treatment in terms of clinical recurrence rate and long-term patency of the sinus.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: NeurointerventionalExperimental Treatment1 Intervention
Stenting of the venous sinus is the neuro-interventional treatment that is being offered to patients with idiopathic intracranial hypertension that are refractory to medical management.

Find a Location

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor
575 Previous Clinical Trials
3,094,848 Total Patients Enrolled
~3 spots leftby Nov 2025